@article {7553,
	title = {Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma},
	journal = {Blood Cancer Journal},
	volume = {4},
	year = {2014},
	note = {Cited By :12Export Date: 21 February 2017},
	month = {2014},
	abstract = {Data from two randomized pivotal, phase 3 trials evaluating the combination of lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) were pooled to characterize the subset of patients who achieved long-term benefit of therapy (progression-free survival >=3 years). Patients with long-term benefit of therapy (n = 45) had a median duration of treatment of 48.1 months and a response rate of 100\%. Humoral improvement (uninvolved immunoglobulin A) was more common in patients with long-term benefit of therapy (79\% vs 55\%; P = 0.002). Significant predictors of long-term benefit of therapy in multivariate analysis were age < 65 years (P = 0.03), β2-microglobulin <2.5 mg/l (P = 0.002) and fewer prior therapies (P = 0.002). The exposureadjusted incidence rate (EAIR) of grade 3-4 neutropenia was lower in patients with long-term benefit of therapy (13.9 vs 38.2 per 100 patient-years). The EAIR for invasive second primary malignancy was the same in patients with long-term benefit of therapy and other patients (1.7 per 100 patient-years). These findings indicate that patients with RRMM can experience long-term benefit with lenalidomide and dexamethasone treatment with manageable side effects. {\textcopyright} 2014 Macmillan Publishers Limited All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927949819\&doi=10.1038\%2fbcj.2014.77\&partnerID=40\&md5=340331c3adde9524bdc13ddec10a0778},
	author = {Dimopoulos, M.A. and Swern, A.S. and Li, J.S. and Hussein, M. and Weiss, L. and Nagarwala, Y. and Baz, R.}
}
